This report, written in French, analyzes the production and formulation challenges of Diabenil 5 mg (glibenclamide), an oral antidiabetic treatment for type 2 diabetes. It details the industrial manufacturing steps—including granulation and compression—while highlighting a major safety issue: the risk of severe hypoglycemia caused by the drug's low solubility and irregular absorption. To improve patient safety and drug effectiveness, the authors propose optimization techniques such as micronization to reduce particle size and the use of solubilizing agents to ensure a more controlled and stable release of the active ingredient.